On August 28, 2025, the US Food and Drug Administration (FDA) approved Teva Pharmaceuticals’ generic to Novo Nordisk’s Saxenda® (liraglutide injection). This is the first generic glucagon-like peptide-1 (GLP-1) agonist approved for use as an adjunct to diet and exercise for chronic weight management...
On August 27, 2025, the FDA approved the 2025-2026 formulas of four COVID-19 vaccines and revoked emergency use authorizations (EUAs) for all COVID-19 vaccines. The new limitations for the COVID-19 vaccines mean that individuals...
Studies show that GLP-1's may improve the mental wellbeing of patients with diabetes and/or obesity. Patients using a GLP-1 might see improvements in the quality of life both physically and mentally. It is suspected that GLP-1's may have an impact on patients with...
The FDA recently granted approval to Novo Nordisk’s Wegovy (semaglutide) for the treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH). Approximately 6% of U.S. adults (14.9 million people) have MASH (formerly known as nonalcoholic steatohepatitis [NASH]), and its prevalence is growing...
Mercer, a consulting firm, recently published the results of their new survey. Employers with at least 500 employees were surveyed and according to the results, 51% said they plan to increase cost-sharing in 2026, including raising ...
